Autologous transplantation in elderly patients with multiple myeloma: Are we asking the right questions?

Bone Marrow Transplantation

Volumn 38, Issue 9, 2006, Pages 585-592

  Klepin, H D ^a   Hurd, D D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BORTEZOMIB; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE;

AGE DISTRIBUTION; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; ELDERLY CARE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; GENETIC DIFFERENCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; ONSET AGE; OVERALL SURVIVAL; PATIENT SELECTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33750190049     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705486     Document Type: Review

References (40)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
4. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
5. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myelorna patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
6. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
7. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple mycloma. Blood 1999; 93: 51-54.
8. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
9. Blade J, Munoz M, Fontanillas M, San Miguel J, Alcala A, Maldonado J el al. Treatment of multiple myeloma in elderly people: Long-term results in 178 patients. Age Ageing 1996; 25: 357-361.
10. Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M et al. Multiple myeloma in elderly patients: Presenting features and outcome. Eur J Haematol 2001; 66: 11-17.
11. Clavic, M, Casciaro S, Gatti AM, Spriano M, Bonanni F, Poggi A et al. Multiple mycloma in the elderly: Clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238-244.
12. Nilsson T, Hoglund M, Lenhoff S, Rylander L, Turesson I, Westin J et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003; 120: 960-969.
13. Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951-966.
14. Cohen HJ, Bartolucci A. Age and the treatment of multiple mycloma. Southeastern Cancer Study Group experience. Am J Med 1985; 79: 316-324.
15. Palva IP, Ahrenberg P, Ala-Harja K, Almqvist A, Hanninen A, Ilvonen M et al. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Eur J Haematol 1989; 43: 328-331.
16. Wisloff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad K et al. Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway 1. Eur J Haematol 1991; 47: 333-337.
17. Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple mycloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001; 112: 242-247.
18. Fietz T, Rieger K, Dimeo F, Blau IW, Thiel E, Knauf WU. Stem cell mobilization in multiple myeloma patients: Do we need an age-adjusted regimen for the elderly? J Clin Apher 2004; 19: 202-207.
19. Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 1997; 20: 1-3.
20. Rapoport AP, DiPersio JF, Martin BA, Duerst RE, Kouides PA, Liesveld JL et al. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients
21. Dumontet C, Ketterer N, Espinouse D, Neidhardt EM, Moullet I, Thieblemont C et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037-1041.
22. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H el al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
23. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs > / = 60 years of age. Bone Marrow Transplant 2003; 32: 1135-1143.
24. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917-922.
25. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389-396.
26. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E et al. Autologous stem cell transplantation in multiple myeloma: Improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
27. Facon T, Mary JY, Harousseau J, Huguet F, Berthou C, Grosbois B et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006; 24: 1.
28. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181-200.
29. Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK et al. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996; 6: 399-412.
30. Alamo J, Shahjahan M, Lazarus HM, de Lima M, Giralt SA. Comorbidity indices in hematopoietic stem cell transplantation: A new report card. Bone Marrow Transplant 2005; 36: 475-479.
31. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
32. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912 2919.
33. Inouye SK, Peduzzi PN, Robison IT, Hughes IS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998; 279: 1187-1193.
34. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
35. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963; 185:914-919.
36. Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988; 24: 609-614.
37. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
38. Cesari M, Kritchevsky SB, Penninx BW, Nicklas BJ, Simonsick EM, Newman AB et al. Prognostic value of usual gait speed in well-functioning older people - results from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2005; 53: 1675-1680.
39. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332: 556-561.
40. Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E et al. Physical performance measures in the clinical setting. JAm Geriatr Soc 2003; 51: 314-322.